CMC Services & Analytical Sciences Capabilities
Our multidisciplinary approach combines expert product and process knowledge with a quality-first mindset to ensure Right First Time submissions across the globe.
Comprehensive CMC Support
Kymanox expertise extends to all phases of development and commercialization, including CMC phase-appropriate development strategies and planning for global regulatory submissions.Explore More
Quality Systems & Operations Support
Turnkey documentation development, remediation support for CGMP inspection observations, and PAI support of analytical laboratories and GLP inspections.Explore More
Laboratory Design & Setup
Kymanox offers design and setup of CGMP and GLP analytical laboratories, analytical & microbial method characterization, development, and validation.Start Getting More Done!
CRO / CDMO Selection
Kymanox offers evaluation, selection, and management of contract research organizations (CRO) and contract development and manufacturing organizations (CDMO), including technology transfer.Explore More
Meet our CMC Services & Analytical Sciences Experts
Markets That Benefit from Our CMC Services & Analytical Sciences Solutions
Our experts understand the interaction between devices and drug products. Our experience includes injectables, nasal, respiratory, and more.
We understand why “the product is the process” and how to implement solutions to your unique challenges.
Drug development is constantly evolving with new regulations and technology. We stay up to date to maintain your compliance.
The Kymanox CMC Services & Analytical Sciences Difference
At Kymanox we are more than consultants. We are partners with our clients and create custom solutions that meet each client’s unique needs.
Flexibility & Agility
At Kymanox, we make it easy for clients to get the solutions they need, when they need it. Clients tell us our flexibility is one of the key reasons they keep coming back.
Proven Broad Expertise
Our team of experts is focused on life sciences with extensive experience across drug and device development. No matter your challenge, we can help you conquer it.
Dynamic Project Management
A personalized approach to project management that combines your needs with our proven tools and expertise to create a custom solution for your project.
Frequently Asked CMC Services & Analytical Sciences Questions (FAQs)
Can Kymanox author CMC (Quality) Sections of my IND, NDA, ANDA, or BLA?
Kymanox has an expert staff of regulatory and technical writers who are intimately familiar with authoring the CMC (Quality) sections for all submission types. Kymanox is also well versed in preparing all sections of your submission, as well as Briefing Packages to support communications from Pre-IND through Pre-NDA/BLA.
What other documents can Kymanox author?
The comprehensive CMC support offered by Kymanox includes, but is not limited to, Quality by Design (QbD) documentation including CQAs and CPPs, Target Product Profile (TPP), and Quality TPP (QTPP), as well as Common Technical Document (CTD) Module 3 (i.e., 3.2S and 3.2P) authoring for submission of global investigational products and market authorization.
Can Kymanox handle regulatory submissions outside the US?
Yes, the Kymanox team is experienced with the regional regulatory requirements and expectations for submissions to EU, Japan, Brazil, and Canada.
Can Kymanox help with my pharmaceutical/combination product development and regulatory strategy?
Yes, Kymanox’s expert staff of pharmaceutical development scientists and drug delivery device engineers can provide a breadth of strategic development and regulatory planning services throughout the stages of clinical development and up to market authorization. Kymanox is well versed in navigating the complexities of product development to deliver and maximize the potential for commercial success. These services include, but are not limited to, the evaluation of formulation technologies and selection and optimization of drug product formulation; evaluation of manufacturing process technologies, process development, scale-up, and technology transfer; analytical and microbiological method development and validation support; technical writing of protocols and reports; evaluation, selection, and optimization primary packaging components and drug delivery systems; stability study strategy and design; and the evaluation and selection of contract organizations.
Can Kymanox help with the selection and setup of my laboratory instrumentation and equipment?
Absolutely! The Kymanox Analytical Sciences group has professionals with global experience working with a vast array of laboratory instrumentation and equipment from bench-scale to commercial-scale in the pharmaceutical, biotechnology, medical device, and in vitro diagnostic industries. We provide on-going support for all phases of development, from discovery to post-commercialization, with services ranging from research and selection of instrumentation/equipment that are best suited to your project needs, setup and qualification of instrumentation/equipment intended for GxP use, as well as troubleshooting issues with system performance and/or assay optimization.
Read the Latest at Kymanox
Nathan Blazei Joins Kymanox as Head of Quality
Kymanox, a full-service life sciences solutions provider supporting commercialization of vital medicines and treatments, is proud to announce the addition of Nathan Blazei as Head of Quality. This new role will allow Kymanox to further enhance quality,...
On Demand Webinar: Lessons from Inspiring Women Science Leaders for International Women’s Day
"As women, our ability to pivot and persevere when our lives become disrupted has become a leadership advantage!" ~Jennifer Johns https://kymanox.canto.com/direct/video/lfjpc5oos96hjeis95ger0ib6u/COge77h8J0ePzIoIvDXSggh3J_w/original?conte...
How the FDA Defines Combination Products
Is your product a combination product? Combination products are defined in 21 CFR 3.2(e) and more products than ever now fall into this category but many manufacturers are unaware of that fact nine types of combination products. The FDA identifie...